Research and Clinical Trials

GOG 0187: A Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Brief Description  
The purpose of this study is to determine the effectiveness of Paclitaxel in patients who have ovarian stromal cancer.
Who may be Eligible  

  • Histologically confirmed ovarian stromal cancer not amenable to surgery
    • Granulosa cell tumor
    • Granulosa cell theca cell tumor
    • Sertoli-Leydig cell tumor (androblastoma)
    • Gynandroblastoma
    • Unclassified sex cord stromal tumor
    • Sex cord tumor with annular tubules
    • Steroid (lipid) cell tumor
  • Recurrent disease after no more than 1 prior chemotherapy regimen
  • Not pregnant
  • No other prior invasive malignancy in past 5 years except nonmelanoma skin cancer
  • No prior radiotherapy to study lesion
Gynecological Cancer
IRB Number  
Principal Investigator  
Higgins, Robert

For More Information, Contact  Sarah  , Norek
Phone:  (704) 355-1520  Fax:  (704) 355-1188  
Address:1025 Morehead Medical Drive Suite 600 Charlotte, NC 28204